RHHBF - Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

2024-06-26 14:05:02 ET

Summary

• Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024.
• A prior phase 2b study indicated that patients, given GLSI-100 for HER2/neu positive breast cancer, were able to achieve a 100% recurrence free rate.
• The global breast cancer market size is expected to be worth $49.2 billion by 2032.
• Greenwich Life Sciences had cash of $5,505,975 as of March 31st of 2024; Continuous need to raise cash in coming months, like the recently completed $2.5 million private placement agreement made.

Greenwich LifeSciences, Inc. ( GLSI ) is a good biotech to keep an eye on because it is currently in the process of running its phase 3 study known as Flamingo-01. This particular late-stage study is exploring the use of its GLSI-100 immunotherapy candidate for the treatment of patients with HER2/neu positive breast cancer who had residual disease or high-risk pathologic complete response at surgery and who have already been treated with a neoadjuvant and postoperative adjuvant trastuzumab [Herceptin] based treatment....

For further details see: